King Pharmaceutical Settle lawsuit with Core on metaxalone

King Pharma had ended a patent infringement lawsuit filed against CorePharma related to its drug Skelaxin (metaxalone). SKELAXIN® is a muscle relaxant with a low chance of drowsiness or side effectsAll the claims, including Core's counterclaims, were dismissed without prejudice in a New York federal court.After the dismissal was announced in a filing with the Securities and Exchange Commission. Under the terms of a termination agreement King entered with Core on Jan. 2, King will grant Core a nonexclusive license to make and sell a 400 mg metaxalone product, in what amounts to a generic form of Skelaxin.The license will be effective on Jan. 1, 2012, or six months after a third party sells a generic form of Skelaxin, whichever occurs first.The lawsuit was first filed on March 7, 2003. Other suits were filed against Eon Labs Inc. and Mutual Pharmaceutical Co., both of whom King said had filed to make a generic form of Skelaxin.